Join Growin Stock Community!

Revvity, inc.RVTY.US Overview

US StockHealthcare
(No presentation for RVTY)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RVTY AI Insights

RVTY Overall Performance

RVTY AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RVTY Recent Performance

-3.07%

Revvity, inc.

0.05%

Avg of Sector

-0.31%

S&P500

RVTY PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RVTY Key Information

RVTY Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RVTY Profile

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Price of RVTY

RVTY FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RVTY Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.13
PE Ratio (TTM)
47.72
Forward PE
17.21
PS Ratio (TTM)
3.90
PB Ratio
1.52
Price-to-FCF
21.27
METRIC
VALUE
vs. INDUSTRY
Gross Margin
54.77%
Net Margin
8.45%
Revenue Growth (YoY)
3.67%
Profit Growth (YoY)
1.74%
3-Year Revenue Growth
1.37%
3-Year Profit Growth
-1.13%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.13
PE Ratio (TTM)
47.72
Forward PE
17.21
PS Ratio (TTM)
3.90
PB Ratio
1.52
Price-to-FCF
21.27
Gross Margin
54.77%
Net Margin
8.45%
Revenue Growth (YoY)
3.67%
Profit Growth (YoY)
1.74%
3-Year Revenue Growth
1.37%
3-Year Profit Growth
-1.13%

  • When is RVTY's latest earnings report released?

    The most recent financial report for Revvity, inc. (RVTY) covers the period of 2025Q4 and was published on 2025/12/28. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RVTY's short-term business performance and financial health. For the latest updates on RVTY's earnings releases, visit this page regularly.

  • Where does RVTY fall in the P/E River chart?

    According to historical valuation range analysis, Revvity, inc. (RVTY)'s current price-to-earnings (P/E) ratio is 45.25, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of RVTY?

    According to the latest financial report, Revvity, inc. (RVTY) reported an Operating Profit of 111.75M with an Operating Margin of 14.47% this period, representing a decline of 5.9% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is RVTY's revenue growth?

    In the latest financial report, Revvity, inc. (RVTY) announced revenue of 772.06M, with a Year-Over-Year growth rate of 5.85%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does RVTY have?

    As of the end of the reporting period, Revvity, inc. (RVTY) had total debt of 3.37B, with a debt ratio of 0.28. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RVTY have?

    At the end of the period, Revvity, inc. (RVTY) held Total Cash and Cash Equivalents of 919.86M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does RVTY go with three margins increasing?

    In the latest report, Revvity, inc. (RVTY) achieved the “three margins increasing” benchmark, with a gross margin of 54.6%%, operating margin of 14.47%%, and net margin of 12.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess RVTY's profit trajectory and future growth potential.

  • Is RVTY's EPS continuing to grow?

    According to the past four quarterly reports, Revvity, inc. (RVTY)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.86. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RVTY?

    Revvity, inc. (RVTY)'s Free Cash Flow (FCF) for the period is 161.79M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 8.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of RVTY?

    The latest valuation data shows Revvity, inc. (RVTY) has a Price-To-Earnings (PE) ratio of 45.25 and a Price/Earnings-To-Growth (PEG) ratio of 0.24. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.